Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
Follow ZTS
Zoetis Inc. (ZTS) EBITDA
Zoetis Inc.'s EBITDA for fiscal 2025 was $4.1B, up 5.55% from $3.9B in fiscal 2024. Over the twelve months to 30 June 2026 it was $4.0B. Over the past ten years it has ranged from $868.0M (fiscal 2015) to $4.1B (fiscal 2025) — the current reading is the highest in ten years. EBITDA has risen for 10 consecutive fiscal years. Zoetis Inc. ranks 3rd of 83 Drug Manufacturers Specialty & Generic companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $4.1B | 5.55% |
| FY2024 | $3.9B | 5.16% |
| FY2023 | $3.7B | 9.69% |
| FY2022 | $3.3B | 5.76% |
| FY2021 | $3.2B | 18.44% |
| FY2020 | $2.7B | 9.52% |
| FY2019 | $2.4B | 10.53% |
| FY2018 | $2.2B | 13.49% |
| FY2017 | $1.9B | 18.85% |
| FY2016 | $1.6B | 88.25% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $1.0B | 11.40% |
| Mar 2026 | $939.0M | (2.80%) |
| Dec 2025 | $966.0M | (9.55%) |
| Sep 2025 | $1.1B | (1.93%) |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $8.3B |
| HLN Haleon PLC Sponsored ADR compare | $4.3B |
| ZTS Zoetis Inc. | $4.0B |
| VTRS Viatris Inc. compare | $2.7B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $2.5B |
| UTHR United Therapeutics Corporation compare | $1.5B |
| NBIX Neurocrine Biosciences, Inc. compare | $832.4M |
| ELAN Elanco Animal Health Incorporated compare | $774.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $596.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ZTS
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement